Tag archive for ‘Douglas Tsao’
Shiri Habib-Valdhorn On Wednesday, July 30th, 2014

Barclays Pharmaceuticals Analyst: Teva Must Be Aggressive with Acquisitions

– Barclays analyst Douglas Tsao sees the success of double-dose Copaxone as a platform for expansion. – “The mergers and acquisition phenomenon is one of the most notable trends in the global pharmaceutical More...

CFO Eyal Desheh, TEVA
Shiri Habib-Valdhorn On Thursday, December 5th, 2013

Analysts Unenthusiastic Over Teva’s NTE Products

– Teva sees $3 billion in potential sales by 2020 from 50 new therapeutic entities. – Dr. Michael Hayden – 50 new products with $3 billion in potential sales in 2020 is the news delivered More...

Wordpress site Developed by Fixing WordPress Problems